UK Court Shakes Up Test For Equivalent Infringement In Lilly/Actavis Case
Executive Summary
The UK Supreme Court has shaken up the test for equivalent infringement in the UK, which is good news for patent owners out to catch infringers.
You may also be interested in...
Lilly Loses UK High Court Alimta Battle
Eli Lilly & Co. will continue to "vigorously defend" its Alimta (pemetrexed disodium) patents in the UK, France, Italy and Spain, it said, following a UK High Court ruling last week that will allow competitor Actavis to market a generic version of the cancer drug.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.